BRPI1008415A2 - uso de cardiotrofina-1 para o tratamento de doenças metabólicas - Google Patents

uso de cardiotrofina-1 para o tratamento de doenças metabólicas

Info

Publication number
BRPI1008415A2
BRPI1008415A2 BRPI1008415-0A BRPI1008415A BRPI1008415A2 BR PI1008415 A2 BRPI1008415 A2 BR PI1008415A2 BR PI1008415 A BRPI1008415 A BR PI1008415A BR PI1008415 A2 BRPI1008415 A2 BR PI1008415A2
Authority
BR
Brazil
Prior art keywords
cardiotrophin
treatment
metabolic diseases
insulin
hyperglycaemias
Prior art date
Application number
BRPI1008415-0A
Other languages
English (en)
Inventor
María Prieto Valtueña Jesus
Jesús Moreno Aliaga Maria
Bustos De Abajo Matilde
Original Assignee
Proyecto De Biomedicina Cima S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima S.L. filed Critical Proyecto De Biomedicina Cima S.L.
Publication of BRPI1008415A2 publication Critical patent/BRPI1008415A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI1008415-0A 2009-02-12 2010-02-10 uso de cardiotrofina-1 para o tratamento de doenças metabólicas BRPI1008415A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900396 2009-02-12
ESP200900396 2009-02-12
PCT/ES2010/070072 WO2010092218A2 (es) 2009-02-12 2010-02-10 Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas

Publications (1)

Publication Number Publication Date
BRPI1008415A2 true BRPI1008415A2 (pt) 2018-02-27

Family

ID=42562119

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008415-0A BRPI1008415A2 (pt) 2009-02-12 2010-02-10 uso de cardiotrofina-1 para o tratamento de doenças metabólicas

Country Status (11)

Country Link
US (1) US20110293562A1 (pt)
EP (1) EP2397152B1 (pt)
JP (1) JP2012517459A (pt)
CN (1) CN102316892B (pt)
AU (1) AU2010212794A1 (pt)
BR (1) BRPI1008415A2 (pt)
CA (1) CA2750074A1 (pt)
ES (1) ES2493618T3 (pt)
MX (1) MX2011008562A (pt)
RU (1) RU2011137413A (pt)
WO (1) WO2010092218A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419916B2 (en) 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
CN106255748A (zh) * 2014-02-24 2016-12-21 释放能量医药股份有限公司 诱导人褐色脂肪细胞祖细胞分化的方法和组合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
EP0179904A1 (en) 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
EP1053020B1 (en) 1998-01-29 2004-03-31 Poly-Med Inc. Absorbable microparticles
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
WO2004011621A2 (en) * 2002-07-29 2004-02-05 Es Cell International Pte Ltd. Multi-step method for the differentiation of insulin positive, glucose
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
JP2008533101A (ja) * 2005-03-17 2008-08-21 ノボ ノルディスク アクティーゼルスカブ 肥満の治療において使用するための化合物
AU2007214708A1 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments

Also Published As

Publication number Publication date
ES2493618T3 (es) 2014-09-12
EP2397152A2 (en) 2011-12-21
CN102316892A (zh) 2012-01-11
CN102316892B (zh) 2014-06-04
RU2011137413A (ru) 2013-03-20
US20110293562A1 (en) 2011-12-01
AU2010212794A1 (en) 2011-08-11
WO2010092218A2 (es) 2010-08-19
MX2011008562A (es) 2011-09-09
CA2750074A1 (en) 2010-08-19
WO2010092218A3 (es) 2010-11-18
JP2012517459A (ja) 2012-08-02
EP2397152B1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
CY1123253T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν αναστολεα του sglt2, εναν αναστολεα της dpp-iv και προαιρετικα εναν επιπλεον αντιδιαβητικο παραγοντα και χρησεις αυτης
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
WO2007009389A3 (fr) Derives de propanamide substitues, preparation et utilisation de ces derives
CL2007002187A1 (es) Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
ATE477819T1 (de) Verwendung von organischen verbindungen
BRPI1008415A2 (pt) uso de cardiotrofina-1 para o tratamento de doenças metabólicas
EA201490982A1 (ru) Аналоги глюкагона
WO2008108958A8 (en) Benzimidazole derivatives and methods of use thereof
WO2006053043A3 (en) Methods of treating diabetes mellitus
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
BRPI0606228A2 (pt) inibidores de enzima 11-beta-hidroxiesteróide desidrogenase tipo 1
BR112017013465A2 (pt) derivado de biarila, e, composição farmacêutica.
EA200900345A1 (ru) Замещенные ациланилиды и способы их применения
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
CY1110928T1 (el) Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις
Notarius et al. Effect of fitness on reflex sympathetic neurovascular transduction in middle-age men.
BRPI0911497A2 (pt) derivados de nip tiazol como inibidores de 11-beta-hidroxiesteroide desidrogenase-1.
UA85405C2 (ru) Производные 1,1'-(1,2-этиндиил)бис-бензола как ингибиторы ртр-1в
WO2008111956A3 (en) Fatty acid oxidation inhibitors treating hyperglycemia and related disorders
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
TW200640842A (en) Derivatives of aminobutanoic acid inhibiting CPT
DE602004018352D1 (de) Therapeutische anwendungen für c-peptid
WO2010007085A3 (en) Use of gcn5 inhibitors in medicine
WO2007130431A3 (en) FUNCTION OF ESTROGEN RELATED RECEPTOR GAMMA (ERRγ) IN INCREASING MITOCHONDRIAL BIOGENESIS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: PROYECTO DE BIOMEDICINA CIMA S.L. (ES) ; INSTITUTO

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: PROYECTO DE BIOMEDICINA CIMA S.L. (ES) ; INSTITUTO

B25B Requested transfer of rights rejected

Owner name: PROYECTO DE BIOMEDICINA CIMA S.L. (ES) ; INSTITUTO